Search
Delapril
go.drugbank.com/drugs/DB13312InvestigationalCategories: Agents Acting on the Renin-Angiotensin SystemSuvecaltamide
go.drugbank.com/drugs/DB19139InvestigationalSuvecaltamide is under investigation in clinical trial NCT05122650 (A Study to Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)).
Synonyms: 4-(1-methylethyl)-n-((1r)-1-(5-(2,2,2-trifluoroethoxy)-2-pyridinyl)ethyl)benzeneacetamide, Benzeneacetamide, 4-(1-methylethyl)-n-((1r)-1-(5-(2,2,2-trifluoroethoxy)-2-pyridinyl)ethyl)-JNJ-26489112
go.drugbank.com/drugs/DB15203InvestigationalJNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive
Radium Ra-223
go.drugbank.com/drugs/DB12813InvestigationalRadium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).
R-348
go.drugbank.com/drugs/DB06321InvestigationalSynonyms: 5-Fluoro-N-(4-methyl-3-propionylaminosulfonylphenyl)-N'-(4-(prop-2-ynyloxy)phenyl)-2,4-pyrimidinediamineAdipiplon
go.drugbank.com/drugs/DB06579InvestigationalAdipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.
NS-3728
go.drugbank.com/drugs/DB05835ExperimentalNS3728 is an orally active chloride channel blocker for the treatment of cancer.
Synonyms: N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]ureaClocapramine
go.drugbank.com/drugs/DB09003ExperimentalClocapramine is an atypical antipsychotic of the imidobenzyl class which was introduced in Japan in 1974 for the treatment of schizophrenia. … In addition to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and panic.
Betaxolol
go.drugbank.com/drugs/DB00195ApprovedInvestigationalA cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
NTx-265
go.drugbank.com/drugs/DB05649InvestigationalIn May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. … NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause